Pharmaceuticals
Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Analysis
Australia's Paroxysmal Nocturnal Hemoglobinuria (PNH) therapeutics market is expected to grow from $44 Mn in 2022 to $108 Mn in 2030 with a CAGR of 11.70% for the year 2022-2030. The therapeutic choices available to patients have considerably improved as a result of recent developments in the development of targeted medicines for PNH in Australia, such as complement inhibitors. The market is segmented by therapy, diagnostic test, by distribution channel. Some key players in this market include Mayne Pharma, Mesoblast, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Akari Therapeutics, Amgen, CSL Behring, and Bioverativ.
Buy Now
Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Executive Summary
Australia's Paroxysmal Nocturnal Hemoglobinuria (PNH) therapeutics market is expected to grow from $44 Mn in 2022 to $108 Mn in 2030 with a CAGR of 11.70% for the year 2022-30. The expected overall health spending in Australia for 2022-23 is $105.8 Bn, or 16.8% of all government spending in the country. The health sector contributes 10%, or around $105 Bn in fiscal year 2022, to Australia's economy.
In Australia, there will be 1.6 PNH cases for per million people in 2022. A rare and deadly blood condition known as Paroxysmal Nocturnal Hemoglobinuria (PNH), which is brought on by mutations in the PIG-A gene, disrupts the creation of red blood cells. PNH can result in a number of symptoms, such as exhaustion, breathlessness, abdominal pain, and blood clots, as well as serious side effects including kidney damage and stroke. PNH is regarded as a rare condition in Australia, and there aren't many people who have it. However, the disorder necessitates specialized medical care and therapy and can have a substantial influence on patients' quality of life. In Australia, managing and treating PNH often involves a multidisciplinary team that includes hematologists, experts in blood diseases, and other medical personnel. Blood transfusions, anticoagulant therapy to avoid blood clots, and immunosuppressive therapy to minimize red blood cell oxidation are all possible treatment choices.
Market Dynamics
Market Growth Drivers
The therapeutic choices available to patients have considerably improved as a result of recent developments in the development of targeted medicines for PNH in Australia, such as complement inhibitors. It is anticipated that these novel treatments would fuel market expansion in Australia. Drug discovery and approval for uncommon disorders like PNH are supported by the Australian regulatory system. Because of this, manufacturers are now more likely to spend money in Australia on the development of PNH treatments. The rise of the PNH therapeutics market has been aided by the Australian government's increased spending on healthcare. As a result, PNH sufferers now have improved access to medical services and therapies.
Market Restraints
PNH is a rare condition, and Australia only has a limited number of persons that suffer from it. Due to the reduced patient pool, it may be challenging for manufacturers to recover their costs associated with developing PNH medicines. PNH can now be treated with anticoagulant medication and blood transfusions, which may reduce the need for more advanced and expensive PNH medicines. The time to market for PNH treatments in Australia may be impacted by the regulatory process for the approval of new pharmaceuticals, which can be drawn out and complicated. This may slow the release of novel treatments and restrain the market for PNH therapeutics from expanding.
Competitive Landscape
Key Players
- Mayne Pharma (AU)
- Mesoblast (AU)
- Alexion Pharmaceuticals
- Alnylam Pharmaceuticals
- Akari Therapeutics
- Amgen
- CSL Behring
- Bioverativ
Healthcare Policies and Regulatory Landscape
The national regulatory organisation in charge of policing the importation, production, and distribution of drugs in Australia is the Central Drugs Standard Control Organisation (CDSCO). The company is in charge of clinical trial rules, post-marketing surveillance, and drug registration and clearance. The National Health Policy (NHP) describes the government's objectives and plans for enhancing Australia's access to and provision of healthcare. The strategy places a strong emphasis on the necessity of expanding access to high-quality, reasonably priced healthcare services, including the availability of necessary medications. The Australian government has compiled a list of essential medications called the National List of Essential Medicines (NLEM) that it believes are required to provide for the general public's basic healthcare needs. The list is updated frequently and is used as a resource for purchasing and paying for medications.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Segmentation
By Therapy
- Medication Therapy
- Stem Cell Therapy
- Blood Transfusion Therapy
By Diagnostic Tests
- CBC
- LHD
- Bone Marrow Examination
- Flow Cytometry
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
- Analyzing historical proprietary data collected from multiple projects.
- Regularly updating our existing data sets with new findings and trends.
- Ensuring data consistency and accuracy through rigorous validation processes.
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
- Searching through academic conferences, published research, citations, and social media platforms
- Collecting and compiling diverse data to build a comprehensive and detailed database
- Continuously updating our database with new information to ensure its relevance and accuracy
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
- Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
- Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
- Continuously refreshing our database to ensure that the information remains current and reliable.
- Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
- Merging historical data from secondary research with real-time data from primary research.
- Conducting thorough data validation and cleansing to remove inconsistencies and errors.
- Organizing data into a structured format that is easily accessible and usable for various applications.
- Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
To request a free sample copy of this report, please complete the form below.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
Related reports (by category)
Pharmaceuticals
Philippines Migraine Drugs Market Analysis
Pharmaceuticals
UK Compression Therapy Market Analysis
Pharmaceuticals
Malaysia Photorejuvenation Market Analysis
Related reports (by geography)
Rare Diseases
Australia Wilson?s Disease Therapeutics Market Analysis
Digital Health
Australia Digital Health Market Analysis
Pharmaceuticals
